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Abstract
Impaired development of embryos produced by somatic cell nuclear transfer (SCNT) is
mostly associated with faulty reprogramming of the somatic nucleus to a totipotent state
and can be improved by treatment with epigenetic modifiers. Here we report that addition of
100 μM vitamin C (VitC) to embryo culture medium for at least 16 h post-activation signifi-
cantly increases mouse blastocyst formation and, when combined with the use of latruncu-
lin A (LatA) during micromanipulation and activation procedures, also development to term.
In spite of this, no significant effects on pluripotency (OCT4 and NANOG) or nuclear repro-
gramming markers (H3K14 acetylation, H3K9 methylation and DNA methylation and hydro-
xymethylation) could be detected. The use of LatA alone significantly improved in vitro
development, but not full-term development. On the other hand, the simultaneous treatment
of cloned embryos with VitC and the histone deacetylase inhibitor psammaplin A (PsA), in
combination with the use of LatA, resulted in cloning efficiencies equivalent to those of VitC
or PsA treatments alone, and the effects on pluripotency and nuclear reprogramming mark-
ers were less evident than when only the PsA treatment was applied. These results suggest
that although both epigenetic modifiers improve cloning efficiencies, possibly through differ-
ent mechanisms, they do not show an additive effect when combined. Improvement of
SCNT efficiency is essential for its applications in reproductive and therapeutic cloning, and
identification of molecules which increase this efficiency should facilitate studies on the
mechanism of nuclear reprogramming and acquisition of totipotency.
Introduction
Somatic cell nuclear transfer (SCNT), to be successful, requires the transferred somatic nucleus
to undergo an orchestrated array of epigenetic modifications leading to changes in the structure
and composition of chromatin. This epigenetic reprogramming, driven by factors present in the
cytoplasm of the recipient oocyte, allows the acquisition of an undifferentiated embryo-like chro-
matin status compatible with embryonic gene activation and embryonic development [1, 2].
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Despite the birth of cloned animals from a variety of species, the low efficiency of SCNT suggests
that epigenetic reprogramming of the somatic nucleus is often incomplete or incorrect, leading
to the developmental arrest of the cloned embryos. Indeed, aberrant DNAmethylation and his-
tone modification patterns have been frequently reported in SCNT embryos [3–9].
In light of the epigenetic abnormalities found in cloned embryos, a new SCNT protocol was
developed to improve reprogramming of the somatic nucleus: the treatment of the donor so-
matic cells or, more often, the reconstructed oocytes with epigenetic modifiers. So far, the most
significant results have been achieved with inhibitors of histone deacetylases (HDACi), such as
trichostatin A, scriptaid, valproic acid or oxamflatin [10–17]. These HDACi treatments increase
histone acetylation levels, resulting in improved chromatin remodeling and accessibility for rep-
lication and transcription factors and, consequently, in significantly higher cloning efficiencies
[18]. The effects on nuclear reprogramming and cloning efficiencies of other epigenetic modifi-
ers, such as inhibitors of DNA or histone methyltransferases, is still uncertain [19–22]. Other re-
cent technical improvements to the SCNT protocol, such as the use of the actin polymerization
inhibitor latrunculin A (LatA) instead of cytochalasin B (CB) to prevent second polar body ex-
trusion, have also contributed to enhanced cloning efficiencies when combined with HDACi
treatments [23–25]. But despite these advancements, the developmental potential of cloned em-
bryos is still suboptimal, hindering the widespread application of SCNT technology.
Vitamin C (VitC), also known as L-ascorbic acid, is a well-known antioxidant that protects
the cells against oxidative stress. Many reports have shown its beneficial effects when added to
oocyte maturation or embryo culture media [26–31]. Recent studies have shown that VitC has
also a positive role in nuclear reprogramming of differentiated cells towards a pluripotent state.
In particular, VitC improves the generation of induced pluripotent stem cells (iPSCs) from both
mouse and human somatic cells [32] and promotes the conversion of partially reprogrammed
mouse iPSCs to a fully reprogrammed state [33]. The effect of VitC on reprogramming seems to
be independent of its antioxidant effect and may rather be explained by a combined enhance-
ment of Jumonji-domain-containing histone demethylases (JHDMs) and ten-eleven transloca-
tion (TET) methylcytosine dioxygenases activities [34–37], which promote histone and DNA
demethylation, respectively, and lead to changes in chromatin structure and gene expression
[38, 39]. The positive role of VitC on the in vitro development of SCNT porcine embryos and
their nuclear reprogramming, in terms of histone acetylation and pluripotency markers expres-
sion, has also been proved [29, 31, 40], but its effects on DNA and histone methylation and full-
term development of the cloned embryos has yet to be demonstrated. On the other hand, VitC
seems not to improve the in vitro development of SCNT embryos from other mammalian spe-
cies, but rather negatively affect it [41, 42].
We have recently reported that the HDACi psammaplin A (PsA), a natural compound iso-
lated from a marine sponge [43], results in enhanced rates of full-term development of cloned
mouse embryos [25]. Given that PsA and VitC act on different epigenetic modifying enzymes,
and that the cooperation of multiple pathways is needed to coordinate reprogramming of vari-
ous epigenetic modifications during SCNT [39], we hypothesized that both compounds could
act synergistically in improving nuclear reprogramming of SCNT embryos. On the other hand,
the antioxidant role of VitC may enhance the HDAC inhibitory activity of PsA, as it has been
reported that reduction of PsA after its uptake into cells is essential for its HDACi activity [44].
Thus, the aims of this study were to explore the effect of VitC on mouse SCNT efficiency,
and to investigate whether the combination of VitC and PsA treatments has a synergistic effect.
To this aim, SCNT mouse embryos were treated with VitC, PsA or the combination of both
(VitC-PsA) and in vitro development, blastocyst cell numbers, epigenetic modifications
(H3K14 acetylation, H3K9 dimethylation and DNAmethylation and hydroxymethylation),
levels of pluripotency (OCT4 and NANOG) and trophectoderm (CDX2) markers, reduced
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glutathione content, and full-term development were assessed. Additionally, the effect of LatA
on both in vitro and in vivo development of untreated and treated embryos was investigated.
Material and Methods
Unless otherwise indicated, all reagents were purchased from Sigma (Madrid, Spain).
Animals
Mouse care and procedures were conducted according to the protocols approved by the Ethics
Committee on Animal and Human Research of the Universitat Autònoma de Barcelona and by
the Departament de Medi Ambient i Habitatge of the Generalitat de Catalunya (Permit num-
bers: 6064 and 5044).
Hybrid B6CBAF1 (C57Bl/6xCBA/J) mice aged 6–12 weeks were used as sperm, oocytes and
cumulus cells donors. Outbred CD1 females mated with normal or vasectomised CD1 males
were used as foster or surrogate mothers, respectively. All animals were purchased from
Charles River (L’Arbresle, France).
Collection of sperm, oocytes and cumulus cells
Spermatozoa were collected from the cauda epididymes in a drop (500 μl /epididymis) of
Hepes-buffered CZB medium (HCZB) [45] covered with oil, and were allowed to disperse dur-
ing 20 min at 37°C. The sperm suspension was then diluted in vials of fresh HCZB (1:2 dilu-
tion), which were directly plunged into liquid nitrogen without cryoprotection. Sperm samples
were stored at -80°C for up to one month.
Oocytes and cumulus cells were collected just before use. Females were induced to super-
ovulate by intraperitoneal injection of 5 IU of pregnant mare serum gonadotropin (Intervet,
Barcelona, Spain) followed 48 h later by 5 IU of human chorionic gonadotropin (hCG; Farma-
Lepori, Barcelona, Spain). Metaphase II oocytes were collected from the oviducts 14–15 h after
hCG administration in HCZB, and treated with 300 U/ml hyaluronidase in HCZB at 37°C
until dispersion of cumulus cells. Denuded oocytes were then washed and kept in drops of
KSOM culture medium (MR-106-D; Millipore, Madrid, Spain) covered with mineral oil at 37°
C under 5% CO2. Dispersed cumulus cells were removed from hyaluronidase, diluted in HCZB
and centrifuged for 5 min at 250 g. The pellet was then resuspended in a small volume of 3%
(v/v) polyvinylpyrrolidone (PVP) in HCZB and kept at 4°C until use.
Intracytoplasmic sperm injection (ICSI)
Sperm samples were thawed at room temperature and 5–10 μl of the concentrated sperm sus-
pension were introduced into a microdrop of 3% PVP. Oocytes were transferred to a micro-
drop of HCZB and injected with a sperm head, decapitated by the freeze/thaw procedure [46].
Injections were performed using blunt-end mercury-filled pipettes (outer diameter 5–6 μm) at-
tached to a piezo impact drill (Burleigh, Mississauga, Canada) driven by a micromanipulation
device (TransferMan NK2; Eppendorf, Hamburg, Germany) installed on an Olympus IX71 mi-
croscope (Olympus, Hospitalet del Llobregat, Spain). Injected oocytes were allowed to recover
for 15 min and then were extensively washed and cultured in KSOM.
Somatic cell nuclear transfer (SCNT)
Oocytes were enucleated and injected with a cumulus cell nucleus using blunt-end mercury-
filled pipettes (outer diameter 8–10 μm and 5–6 μm, respectively) attached to a piezo impact
drill driven by the aforementioned micromanipulation equipment. Micromanipulations were
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performed in groups of 25–30 oocytes in drops of HCZB containing either 5 μg/ml CB or 5 μM
LatA (Santa Cruz Biotechnology, Heidelberg, Germany). Afterwards, the reconstructed oocytes
were extensively washed and cultured for 1–3 h in KSOM supplemented or not with the epige-
netic modifiers before activation.
Chemical activation of reconstructed oocytes was performed by incubating them for 6 h
(37°C, 5% CO2) in 10 mM SrCl2 in Ca
2+free-CZB medium supplemented with either 5 μg/ml
CB or 5 μM LatA to prevent second polar body extrusion. After activation, oocytes showing at
least one pronucleus were extensively washed and cultured in KSOM with or without the
epigenetic modifiers.
Epigenetic modifier treatments of cloned embryos
VitC (L-ascorbic acid, Sigma A5960) was dissolved in tri-distilled water to prepare a 5 mg/ml
stock solution, filtered, and stored at 4°C for up to 3 weeks. PsA (Santa Cruz Biotechnology
258049, Heidelberg, Germany) was dissolved in DMSO to prepare a 3 mM stock solution and
stored frozen. The final concentrations of both epigenetic modifiers were prepared by dilution
of the stock solutions in the culture or activation media, depending on the experimental proce-
dure. Embryos were exposed to 100 μMVitC during 2–3 h after reconstruction and 6 h of acti-
vation (8–9 h treatment) or during 6 h of activation and 10 h, 18 h or the whole duration of the
posterior culture (16 h, 24 h and 120 h treatments, respectively). Embryos were exposed to 10
μM PsA or the combination of both epigenetic modifiers (VitC-PsA) during 6 h of activation
and 10 h of the posterior culture (16 h treatment). At the end of the treatments, embryos were
extensively washed in drops of KSOM culture medium.
Blastocyst differential staining and cell counts
Cloned embryos that reached the blastocyst stage 96 h post-activation in the first set of experi-
ments were used for the differential staining of trophectoderm (TE) and inner cell mass (ICM)
cells, as previously described [47]. Samples were examined with an Olympus IX71 epifluores-
cence microscope fitted with an image capture system (Cell A 2.6, Olympus, Hospitalet del Llo-
bregat, Spain). ImageJ software (Image J 1.45q, Wayne Rasband, National Institutes of Health,
Bethesda, USA) was used for cell counting.
Immunofluorescence staining, image analysis and cell counts
Cloned and ICSI embryos at different developmental stages were fixed and processed for
immunofluorescence detection of H3K14 acetylation (H3K14ac), H3K9 dimethylation
(H3K9me2), 5-methylcytosine (5meC), OCT4, NANOG and CDX2 using previously described
protocols [25]. The immunofluorescence detection of 5-hydroxymethylcytosine (5hmeC) was
also performed, by incubating previously fixed, permeabilized, blocked and 4N HCl-treated
embryos first with a 1:500 dilution of rabbit polyclonal anti-5hmeC primary antibody (Active
motif, La Hulpe, Belgium) overnight at 4°C, and then with 6 μg/mL goat anti-rabbit Alexa
Fluor 594 secondary antibody (Molecular probes, Life technologies, Alcobendas, Spain) for 1h
at room temperature.
H3K14ac was analyzed in cloned embryos at 10 min and 1 h after nuclear transfer, and in
cloned and control ICSI embryos at 16 h, 24 h and 120 h after activation by parthenogenesis or
sperm injection, respectively. H3K9me2 and 5meC were detected in cloned and control ICSI
embryos at 72 h and 120 h after activation. 5meC was also detected at 6 h and 16 h after activa-
tion along with 5hmeC. Finally, NANOG, OCT4 and CDX2 markers were analyzed in cloned
and ICSI blastocysts at 120 h after activation. For each marker analyzed, 15–25 embryos were
used and were stained simultaneously to reduce experimental variability.
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All samples were examined with an Olympus Bx41 (Olympus, Hospitalet del Llobregat,
Spain) epifluorescence microscope fitted with specific filters and an image capture and analyz-
ing system (Isis software version 5.4.5, Metasystems, Boston, USA). For each antibody, images
were acquired using the same exposure times and settings for all embryos and analyzed with
ImageJ software (Image J 1.45q, Wayne Rasband, National Institutes of Health, Bethesda,
USA) for cell counts (NANOG and OCT4/CDX2 double staining of blastocysts) and fluores-
cence quantification. All individual nuclei of embryos at 1-cell, 2-cell and morula stages and 30
nuclei of random regions per blastocyst were outlined for mean fluorescence
intensity calculation.
Quantification of reduced glutathione content in cloned embryos
Non-fluorescent monochlorobimane (MCB) bounds to reduced glutathione (GSH) in a reac-
tion catalyzed by glutathione-s-transferase and forms a fluorescent adduct whose fluorescence
intensity gives a measure of GSH content. Non-treated and treated cloned embryos (18–21 em-
bryos per group) at 16 h post-activation were incubated with 50 μMMCB in KSOM for 40 min
at 37°C. Then, embryos were washed in PBS, fixed in 4% (v/v) paraformaldehyde in PBS for
15 min and mounted onto a glass microscope slide in a microdrop of Vectachield (Vector Lab-
oratories, Inc., Peterborough, UK). Samples were examined with an Olympus Bx41 (Olympus,
Hospitalet del Llobregat, Spain) epifluorescence microscope fitted with an image capture and
analyzing system (Isis software version 5.4.5, Metasystems, Boston, USA). Images were ac-
quired using the same exposure times and settings for all embryos and analyzed with ImageJ
software (Image J 1.45q, Wayne Rasband, National Institutes of Health, Bethesda, USA) for
fluorescence quantification. All individual nuclei were outlined for mean fluorescence
intensity calculation.
Embryo transfer
CD-1 female mice were mated with vasectomized males of the same strain and those with a vag-
inal plug were used as recipients at 0.5 day postcoitum. Between 9–10 two-cell cloned embryos
were co-transferred with one parthenogenetic embryo into each oviduct of each female [48]. As
control for the embryo transfer procedure, 6 in vivo fertilized embryos per oviduct were also
transferred to other pseudo-pregnant recipients. The pups and their corresponding placentas
were delivered by cesarian section at 19.5 days postcoitum and weighted in an analytical scale.
Finally, the cloned pups were fostered to CD-1 mothers that had given birth the day before.
Statistical analysis
Each experiment was repeated at least three times and the results obtained were pooled. Data
on in vitro and in vivo embryonic development were analyzed by chi-square test or Fisher’s
exact test. Comparisons of blastocyst cell numbers, fluorescence intensity and body and placen-
ta weights were performed by Kruskall-Wallis test. In all cases, the GraphPad InStat program
(version 3.05 for windows 95, GraphPad Software, La Jolla, USA) was used. A probability value
of p< 0.05 was considered statistically significant.
Results
In vitro development and blastocyst quality of cloned embryos treated
with VitC for various durations
In a first set of experiments, cloned embryos were treated with 100 μMVitC during 8–9 h,
16 h, 24 h and 120 h to determine the best treatment duration in terms of embryo development
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in vitro and blastocyst quality. In these experiments, CB was used during micromanipulation
and activation procedures.
We found that the addition of VitC to embryo culture medium for at least 16 h post-activa-
tion significantly increased blastocyst rates and the mean number of ICM cells at 96 h post-ac-
tivation compared with non-treated cloned embryos (Table 1). Blastocyst total cell numbers
were also increased, but the results were only significant for the 16 h and 120 h treatments.
Blastocyst formation rates and quality were not significantly affected by extending VitC treat-
ment beyond 16 h, as 16 h, 24 h and 120 h treatments resulted in equivalent developmental
rates and blastocyst cell numbers. Based on these results, we selected the shorter of these treat-
ments (16 h) for further experiments.
In vitro development of cloned embryos treated with a combination of
VitC and PsA
In a second set of experiments, aimed to investigate whether there is an additive effect between
VitC and PsA treatments, cloned embryos were treated with 100 μMVitC, 10 μM PsA or the
combination of both (VitC-PsA) during 16 h and their in vitro development was assessed.
LatA, instead of CB, was used during micromanipulation and activation procedures in
these experiments.
We found that the use of LatA significantly increased the blastocyst rate of non-treated
cloned embryos (45.5%, Table 2) when compared with the use of CB in the previous experi-
ments (26.7%, Table 1). In the case of VitC-treated embryos, blastocyst rates were also in-
creased, but only moderately (52.1%, Table 2 vs. 42.6%, Table 1). As a result, no significant
differences in blastocyst formation rates could be detected in this second set of experiments be-
tween non-treated and VitC-treated embryos. In spite of this, blastocyst rates in the non-treat-
ed group were significantly lower than those in the control ICSI group, whereas between the
VitC-treated and the ICSI groups they were similar (Table 2).
The combined VitC-PsA treatment did not significantly improve the results obtained when
using VitC alone, but it showed higher rates of blastocyst development than when using PsA
alone (Table 2). Indeed, VitC resulted in significantly higher blastocyst rates than PsA. When
compared to non-treated embryos, VitC-PsA was the only treatment in this second set of ex-
periments producing higher blastocyst rates.
Table 1. Effect of different durations of 100 μM VitC treatment on the in vitro development and quality of cloned mouse embryos.
No. activated embryos
developed to (%)
Mean cell number (±SEM) 96 h p.a.
Group No. reconstructed No. activated (%) Two cell Morula Blastocyst No. blastocysts ICM TE Total
NT 186 176 (94.6)a 143 (81.3)a,b 111 (63.1)a,b 47 (26.7)a 46 10.7±0.7a 24.9±1.5a 35.6±2.1a
VitC 8–9 h 206 200 (97.1)a 159 (79.5)a 112 (56.0)a 71 (35.5)a,b 39 12.8±0.9a,b 26.2±1.7a,b 39.0±2.4a,b
VitC 16 h 219 209 (95.4)a 188 (90.0)c 152 (72.7)b,c 89 (42.6)b,c 45 15.0±0.7b 31.5±1.3a,b 46.4±1.8b
VitC 24 h 218 208 (95.4)a 184 (88.5)b,c 149 (71.6)b,c 92 (44.2)b,c 43 14.3±0.7b 31.4±1.5a,b 45.7±2.1a,b
VitC 120 h 214 207 (96.7)a 186 (89.9)c 159 (76.8)c 95 (45.9)c 47 15.3±0.8b 32.8±1.5b 43.1±2.1b
NT: non-treated cloned embryos; p.a.: post-activation
a-c Values with different superscripts differ signiﬁcantly within the same column (p < 0.05; Chi-square test for embryonic development and Kruskall-Wallis
for blastocysts cell numbers).
doi:10.1371/journal.pone.0120033.t001
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Global histone acetylation and methylation levels and DNAmethylation
and hydroxymethylation levels in treated and non-treated cloned
embryos
ICSI and cloned embryos were fixed at different developmental stages and immunostained for
H3K14ac, H3K9me2, 5meC and 5hmeC marks. With regards to histone acetylation, we ob-
served that H3K14 was highly acetylated in the cumulus cell nucleus 10 min after injection, but
its acetylation markedly decreased 1 h after nuclear transfer into the enucleated oocyte
(Fig. 1A). By the end of the treatment with the epigenetic modifiers (16 h post-activation), the
VitC group displayed similar levels of H3K14ac as the non-treated group, both significantly
lower than those of the ICSI group (Fig. 1). VitC-PsA-treated embryos were significantly more
acetylated than embryos treated with VitC alone, at levels equivalent to those of PsA-treated
cloned embryos and ICSI embryos. At the 2-cell stage (24 h post-activation), no significant dif-
ferences were detected between treated and non-treated cloned embryos or among the three
treated groups. In spite of this, only the three groups of treated embryos showed equivalent lev-
els of H3K14ac to the control ICSI group. Finally, at the blastocyst stage (120 h post-activa-
tion), there were no differences between cloned and ICSI embryos, except for PsA-treated
embryos which showed the highest levels of H3K14ac, even when compared with
ICSI controls.
Levels of H3K9me2 were similar between ICSI and cloned embryos and between treated and
non-treated cloned embryos at the two developmental stages analyzed, except for PsA-treated
embryos which showed lower levels than the non-treated and the VitC-PsA groups by 72 h
post-activation, and higher levels than the VitC-PsA group by 120 h post-activation (Fig. 2).
In the case of DNA methylation, we found that non-treated embryos were hypermethylated
compared with ICSI embryos at both morula and blastocyst stages (Fig. 3). The three treat-
ments showed a slight tendency to reduce methylation levels, although it was only statistically
significant for PsA-treated morulae (72 h post-activation), which were significantly less meth-
ylated than non-treated ones. Whereas morulae from all three treatments had similar DNA
methylation levels to ICSI ones, by the blastocyst stage (120 h post-activation) only the PsA-
treated group maintained this similarity.
Finally, we also analyzed DNAmethylation and hydroxymethylation levels at previous
stages of development, and we found that the ratio 5hmeC/5meC of cloned embryos was not
affected by VitC or PsA treatments at 6 and 16 h post-activation (Fig. 4). However, a higher
5hmeC/5meC ratio was found in VitC-PsA treated embryos in comparison with VitC-treated
ones at 16 h post activation.
Table 2. Effect of different epigenetic modiﬁer treatments on the in vitro development of cloned mouse embryos.
No. activated embryos developed to (%)
Group No. reconstructed No. activated (%) Two cell Morula Blastocyst
ICSI 252 248 (98.0)a 237 (95.6)a 170 (68.5)a,b 144 (58.1)a
NT 239 224 (93.7)b 181 (80.8)b 143 (63.8)b,c 102 (45.5)b,c
VitC 16 h 206 194 (94.2)b 174 (89.7)c 149 (76.8)a 101 (52.1)a,b
PsA 16 h 236 201 (85.2)c 166 (82.6)b,c 118 (58.7)c 83 (41.3)c
VitC-PsA 16 h 206 193 (93.7)b 164 (85.0)b,c 145 (75.1)a 109 (56.5)a
NT: non-treated cloned embryos
a-c Values with different superscripts differ signiﬁcantly within the same column (p < 0.05; Chi-square test)
doi:10.1371/journal.pone.0120033.t002
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Levels of pluripotency and trophectoderm markers in treated and non-
treated cloned embryos
In another set of experiments, ICSI and cloned embryos were fixed at 120 h post-activation
and immunostained for OCT4 and NANOG pluripotency markers and the trophectoderm
marker CDX2.
Although ICSI and non-treated cloned blastocysts had equivalent percentages of NANOG
and OCT4 positive cells, global levels of NANOG and OCT4 were significantly lower in non-
Fig 1. Psammaplin A, but not vitamin C, increases H3K14 acethylation at 16 h post-activation. ICSI embryos and cloned embryos non-treated (NT) and
treated with 100 μM vitamin C (VitC), 10 μM psammaplin A (PsA) or the combination of both (VitC-PsA) during 16 h were immunostained for H3K14ac and
DNA detection. A) Representative images of DNA and H3K14ac staining. Scale bar = 20 μm. B) Average intensity of H3K14ac/DNA signal ratio (+SEM)
relative to ICSI embryos.
doi:10.1371/journal.pone.0120033.g001
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treated cloned blastocysts than in ICSI ones (Figs. 5 and 6). VitC treatment alone did not im-
prove NANOG and OCT4 levels, nor the percentage of NANOG and OCT4 positive cells. In
contrast, PsA treatment alone significantly increased the level of the two pluripotency markers,
especially of OCT4 (1.3-fold increase), and the percentage of OCT4 positive cells, to levels
equivalent to those of ICSI embryos. Cloned embryos undergoing the combined treatment
VitC-PsA showed significantly increased levels of OCT4, but not of OCT4 positive cells, and a
significantly higher percentage of NANOG positive cells, but not of NANOG levels.
Fig 2. Psammaplin A, but not vitamin C, reduces H3K9 dimethylation at 72 h post-activation. ICSI
embryos and cloned embryos non-treated (NT) and treated with 100 μM vitamin C (VitC), 10 μM psammaplin
A (PsA) or the combination of both (VitC-PsA) during 16 h were immunostained for H3K9me2 and DNA
detection. A) Representative images of DNA and H3K9me2 staining. Scale bar = 20 μm. B) Average intensity
of H3K9me2/DNA signal ratio (+SEM) relative to ICSI embryos.
doi:10.1371/journal.pone.0120033.g002
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With regards to CDX2, all groups of cloned embryos showed similar levels, which were sig-
nificantly lower than in the ICSI group, and similar percentages of positive cells, which were
equivalent to those of the ICSI group, except for PsA treated embryos which showed a lower
percentage of CDX2 positive cells than non-treated and VitC-treated embryos (Fig. 6).
Reduced glutathione content in treated and non-treated cloned embryos
Cloned embryos were fixed at 16 h post-activation and stained for the quantification of GSH
content as a measure of their reducing potential. We found that the levels of GSH were
Fig 3. Psammaplin A, but not vitamin C, reduces DNAmethylation at 72 h post-activation. ICSI
embryos and cloned embryos non-treated (NT) and treated with 100 μM vitamin C (VitC), 10 μM psammaplin
A (PsA) or the combination of both (VitC-PsA) during 16 h were immunostained for 5meC and DNA detection.
A) Representative images of DNA and 5meC staining. Scale bar = 20 μm. B) Average intensity of 5meC/DNA
signal ratio (+SEM) relative to ICSI embryos.
doi:10.1371/journal.pone.0120033.g003
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significantly higher in embryos treated with VitC alone than in all other groups of cloned em-
bryos. In contrast, treatment with PsA did not alter the GSH content when compared with
non-treated embryos (Fig. 7).
Full-term development of treated and non-treated cloned embryos
Finally, in the last set of experiments cloned embryos were transferred, at the two-cell stage, to
recipient females to assess their full-term development. We found that all three treatments re-
sulted in significantly higher rates of full-term development when compared with the non-
treated group, in which no live clones were born (Table 3). We also found a higher number of
Fig 4. Vitamin C does not alter 5hmeC/5meC ratio. ICSI embryos and cloned embryos non-treated (NT)
and treated with 100 μM vitamin C (VitC), 10 μM psammaplin A (PsA) or the combination of both (VitC-PsA)
during 16 h were immunostained for 5meC and 5hmeC detection. A) Representative images of 5meC and
5hmeC staining. Scale bar = 20 μm. B) Average intensity of 5hmeC/5meC signal ratio (+SEM) relative to
ICSI embryos.
doi:10.1371/journal.pone.0120033.g004
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Fig 5. Psammaplin A, but not vitamin C, increases NANOG levels. ICSI blastocysts and cloned
blastocysts non-treated (NT) and treated with 100 μM vitamin C (VitC), 10 μM psammaplin A (PsA) or the
combination of both (VitC-PsA) during 16 h were immunostained for NANOG and DNA detection.
A) Representative images of DNA and NANOG staining. Scale bar = 20 μm. B) Mean percentage of
blastocyst cells (+SEM) positive for NANOG staining. C) Average intensity of NANOG signal (+SEM) relative
to ICSI embryos.
doi:10.1371/journal.pone.0120033.g005
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Fig 6. Psammaplin A alone or combined with vitamin C increases OCT4 but not CDX2 levels. ICSI blastocysts and cloned blastocysts non-treated (NT)
and treated with 100 μM vitamin C (VitC), 10 μM psammaplin A (PsA) or the combination of both (VitC-PsA) during 16 h were immunostained for OCT4,
CDX2 and DNA detection. A) Representative images of DNA, OCT4 and CDX2 staining. Scale bar = 20 μm. B) Mean percentage of blastocyst cells (+SEM)
positive for OCT4 or CDX2 staining. C) Average intensity of OCT4 and CDX2 signals (+SEM) relative to ICSI embryos.
doi:10.1371/journal.pone.0120033.g006
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residual implantation sites in the recipient females from the treated groups. The number of
pups produced was slightly higher in the VitC-PsA group, but not significantly different from
the other two treatments. Irrespective of the treatment, both fetuses and placentas from the
cloned groups were significantly heavier than those from the fertilized control group.
Fig 7. Vitamin C increases reduced glutathione content.Cloned embryos non-treated (NT) and treated
with 100 μM vitamin C (VitC), 10 μM psammaplin A (PsA) or the combination of both (VitC-PsA) during 16 h
were stained for reduced glutathione content detection at 16 h post-activation. A) Representative images of
monochlorobimane (MCB) staining. Scale bar = 20 μm. B) Average intensity of MCB signal (+SEM) relative to
non-treated embryos.
doi:10.1371/journal.pone.0120033.g007
Table 3. Comparative full-term development and body and placenta weights of fertilized and cloned mouse embryos.
Group No. 2-cell embryos
transferred (recipients)
No. of live
offspring (%)
No. of dead
fetuses (%)
No. of residual
implantation sites (%)
No. of placenta
only (%)
Average weight (mg)
(mean ± SD)
Body Placenta
Control
fertilized
36 (3) 23 (63.9)a 0 (0)a 5 (13.8)a 0 (0)a,b 1359.77 ±
20.12a
121.08 ±
4.78a
NT 258 (16) 0 (0)b 1 (0.4)a 9 (3.5)b 0 (0)a - -
VitC 16h 206 (13) 8 (3.9)c 0 (0)a 46 (22.3)a 4 (1.9)b 1667.99 ±
46.00b
298.71 ±
23.82b
PsA 16h 261 (17) 8 (3.1)c 1 (0.4)a 62 (23.75)a 0 (0)a 1561.84 ±
70.70b
299.78 ±
22.86b
VitC-PsA
16h
203 (13) 10 (4.9)c 0 (0)a 38 (18.7)a 1 (0.5)a,b 1618.34 ±
85.31b
298.54 ±
17.96b
NT: non-treated cloned embryos.
a-c Values with different superscripts within the same column differ signiﬁcantly (Fisher exact test for full-term development and Kruskall-Wallis test with
Dunn post-test for body and placenta weights, p<0.05).
doi:10.1371/journal.pone.0120033.t003
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Of the 26 cloned pups produced, two apparently healthy females from the VitC treatment
were cannibalized by the foster mother, one from the PsA treatment died shortly after birth
due to respiratory problems, one from the VitC-PsA treatment was born prematurely by natu-
ral delivery and was found dead the next day, and three more females from the VitC-PsA treat-
ment died prematurely at a few days of age due to unknown reasons. The other nineteen mice
developed normally to adulthood and were able to reproduce when mated to normal B6CBAF1
males, giving rise to normal litters (3–12 pups).
Discussion
In this study we were able to obtain the first mouse clones from SCNT embryos treated with
VitC and with the combination VitC-PsA, using the actin polymerization inhibitor LatA dur-
ing the micromanipulation and activation procedures. Along with PsA alone, all three treat-
ments resulted in increased numbers of fertile cloned mice.
To determine the optimal duration of the VitC treatment for mouse SCNT, we chose a con-
centration of 100 μM, as it has been reported not to cause embryotoxicity when added to
mouse embryo culture medium, whereas higher concentrations did [27, 41]. On the other
hand, in spite that VitC concentrations over 200 μM have been shown to be beneficial for both
in vitro and in vivo development of SCNT pig embryos in one study [40], Jeong et al. [29]
found that only 100 μMVitC, but not lower (50 μM) or higher (200 μM) concentrations, im-
proved blastocyst formation rates and blastocyst quality in porcine SCNT procedures. A VitC
concentration of 227 μM has also been found to decrease the in vitro development rates of
SCNT bovine embryos [42]. Among the different treatment durations tested in the present
study, 16 h significantly increased blastocyst rates and ICM cell numbers and no further im-
provement was evident by extending the treatment. These results agree with the study of
Huang et al. [40] in porcine SCNT embryos, in which 15 h of treatment with VitC after fusion
was demonstrated to be enough for enhancing preimplantational development, but contrast
with the study of Lee et al. [41] which reported that VitC does not increase the development of
SCNT mouse embryos, probably due to the high concentration used.
Taking into account that reprogramming of the somatic nucleus is thought to occur mainly
within a short period of time after nuclear transfer [49], whereas reactive oxygen species may
accumulate during culture, the fact that a short treatment with VitC after parthenogenetic acti-
vation (16 h) is sufficient to improve cloned embryo development seems to reinforce the idea
that the beneficial effects of VitC may be exerted through improvement of nuclear reprogram-
ming rather than through its antioxidant activity [32]. Indeed, VitC has been reported to en-
hance JHDM and TET activities in mouse and human cells, promoting reduced levels of
histone and DNA methylation [38]. In spite of this, we could not detect any clear improvement
of VitC on the nuclear reprogramming markers H3K14ac, H3K9me2 and 5meC at the develop-
mental stages analyzed, other than a slight increase in H3K14ac at 24 h post-activation and a
slight decrease in DNAmethylation at 72 h post-activation, to levels similar to those of ICSI
embryos. Given that TET-mediated conversion of 5meC into 5hmeC may occur early in devel-
opment [50], we also analyzed 5hmeC at earlier time-points after activation (6 and 16 h) but
did not detect any effect of VitC on this marker either. Other authors have also failed to observe
a substantial decrease in the global levels of 5meC in VitC-treated mouse embryonic stem cells
(ESCs) [36] or cloned porcine embryos at 2-cell, 4-cell and blastocyst stages [51]. According to
Blaschke et al. [36], TET-mediated VitC-induced demethylation seems to be restricted to spe-
cific genomic regions, whereas other regions such as repetitive elements, which cover a large
portion of the genome, are resistant to VitC-induced DNA demethylation and can therefore
obscure the results. In this sense, it is possible that the use of more sensitive and context-
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specific techniques of analysis than immunofluorescence would allow the detection of changes
in DNA methylation levels in the treated embryos, as was indeed observed by Blaschke et al.
[36] when performing 5meC immunoprecipitation followed by deep sequencing, or by Chung
et al. [52] when using DNAmethylation arrays in VitC-treated mouse and human ESCs, re-
spectively. Alternatively, it is also possible that the effect of VitC on DNAmethylation levels in
preimplantational embryos is more limited than in ESCs, as Blaschke et al. [36] also reported
that the stronger effect of VitC in mouse ESCs was found in regions that gain methylation in
cultured ESCs compared to blastocysts, and that are methylated in vivo only after implantation.
Similar arguments could explain the lack of effects of VitC on histone methylation levels ob-
served in the present study, which contrasts with the reduced levels of H3K9 tri- and dimethyla-
tion reported after treatment of mouse pre-iPSCs with VitC [34]. With regards to histone
acetylation, Huang et al. [40] reported increased levels of H4K5 acetylation in VitC-treated por-
cine SCNT embryos at the 2-cell, 4-cell and blastocyst stages. As VitC has not been shown to be
a cofactor for acetyltransferases, and a direct effect of VitC on histone acetylation is therefore
unlikely, histone acetylation levels could be indirectly altered through the effects of VitC on
other epigenetic pathways, but no other epigenetic marks were analyzed in the study by Huang
et al. [40]. In contrast, and in agreement with our results, Chawalit et al. [51] did not detect
changes in H3K9 and K14 acetylation levels in handmade cloned porcine embryos continuously
treated with VitC at any of the stages analyzed (2-cell, 4-cell and blastocysts). These differing re-
sults could be attributed to the specific lysines analyzed (H4K5 in Huang et al. [40] vsH3K9 and
K14 in Chawalit et al. [51] and the present study), and deserve further investigation.
Consistent with the epigenetic results observed, the levels of pluripotency markers OCT4
and NANOG, which are often decreased in cloned embryos [53–55], were not improved in the
blastocysts produced from the VitC-treated SCNT embryos. Again, our results are similar to
those of Blaschke et al. [36] in VitC-treated mouse ESCs and of Chawalit et al. [51] in VitC-
treated handmade cloned porcine embryos, but in disagreement with those of Huang et al. [40]
demonstrating that OCT4 and SOX2 levels were elevated after treatment of cloned porcine em-
bryos with VitC for 15 h after activation. It is noteworthy that despite the treatment with VitC
apparently did not correct the abnormal levels of histone acetylation and of histone and DNA
methylation, nor the defective expression of pluripotency genes, it resulted in a significant in-
crease in full-term development of the treated SCNT embryos compared to the untreated ones.
On the other hand, treatment of cloned embryos with the HDACi PsA also resulted in in-
creased rates of full-term development, similar to those obtained with VitC, which in this case
can be explained by its positive effects on nuclear reprogramming (increased levels of H3K14
acetylation, OCT4 and NANOG; decreased levels of DNA methylation). Nevertheless, none of
the two epigenetic modifiers was able to correct placental overgrowth, a typical feature ob-
served in cloned fetuses [56]. This could be related to an altered trophectoderm lineage, as also
indicated by the low levels of CDX2, a transcription factor essential for trophectoderm and
subsequent placenta formation [57], in all groups of cloned embryos, either treated
or untreated.
It has been reported by Esteban et al. [32] that VitC and the HDACi valproic acid have an
additive effect in improving nuclear reprogramming and mouse iPSCs generation. In contrast,
no additive effect between VitC and another HDACi, trichostatin A, on nuclear reprogram-
ming or blastocyst development was detected in handmade cloned porcine embryos [51]. Al-
though we observed a slightly superior rate of full-term development when VitC and PsA
treatments were combined than when using VitC or PsA separately, the additive effect of these
two epigenetic modifiers on mouse SCNT was not evident. When compared to embryos treated
with VitC alone, embryos treated with VitC-PsA showed some signs of improved nuclear re-
programming, such as increased levels of H3K14ac at 16 h post-activation and of OCT4 in the
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blastocysts produced, at levels equivalent to those of control ICSI embryos. This improvement
can be attributed to the HDACi activity of PsA. Nonetheless, when compared to the treatment
with PsA alone, some of the positive effects of PsA on nuclear reprogramming were not ob-
served when the combined treatment was applied, even though in vitro development of the
VitC-PsA treated embryos was improved. For instance, H3K14ac levels at 120 h post-activation
were much lower in the VitC-PsA-treated embryos than in embryos treated with PsA alone,
and the levels of NANOG, which were increased by the PsA treatment, were unaffected when
VitC and PsA treatments were combined. Further investigation is required to elucidate the rea-
sons for these unexpected results. On the other hand, the intracellular reduction of PsA is es-
sential for its HDACi activity and it has been shown that GSH-depleted cells are not sensitive
to PsA [44]. In this sense, we hypothesized that the antioxidant effect of VitC could increase
embryo reducing potential, thus improving PsA reduction and, consequently, PsA-HDACi ac-
tivity. However, in spite that VitC treatment increased GSH content in cloned embryos as ex-
pected from previous studies [30, 31, 51], no increase in histone acetylation levels or other
synergistic effects with regards to PsA treatment were observed when VitC and PsA treatments
were simultaneously applied. This suggests that the GSH content in the cloned embryos is not
a limiting factor for the HDACi activity of PsA.
Another interesting finding of our study is the effect of LatA on the development of both
treated and untreated cloned embryos. It has been previously reported that LatA increases full-
term development of cloned mouse embryos when compared with CB [24, 25], as it corrects ab-
normal F-actin localization in cloned embryos and decreases the incidence of abnormal chro-
mosome segregation [22, 24]. However, none of these previous studies analyzed the effects of
LatA on in vitro development and in all of them the use of LatA was combined with the treat-
ment of cloned embryos with an epigenetic modifier (either trichostatin A or PsA). To the best
of our knowledge, this is the first report on the effects of LatA on the in vitro development of
cloned embryos, both untreated and treated with an epigenetic modifier. Interestingly, we found
that the use of LatA during micromanipulation and activation procedures increased blastocyst
rates in the non-treated group, but not in the VitC-treated group, in which only a moderate in-
crease was observed. A similar outcome is observed with PsA-treated embryos, in which blasto-
cyst rates are similar with (41.3%, this study) or without (43.2%) [25] the use of LatA. In spite of
their enhanced in vitro development, the full-term development of non-treated embryos was
still suboptimal and no clones could be obtained. Therefore, our results seem to indicate that
LatA enhances in vitro development in those groups of cloned embryos with a more impaired
development (non-treated embryos), but this enhancement is not correlated with improved
full-term development. It is possible that LatA corrects some abnormalities, such as chromo-
some segregation [22], with an impact on preimplantation development, but that other abnor-
malities, such as defective nuclear reprogramming, which are key for implantation and
postimplantation development are not corrected by LatA. This would explain why LatA treat-
ment is only effective in enhancing full-term rates when combined with an epigenetic modifier
such as PsA, which has proved to improve nuclear reprogramming [this study and 25].
Cloning efficiencies obtained in the present study, both for non-treated and treated embry-
os, were not as high as those reported by other authors, which can reach up to 10% for
HDACi-treated embryos. However, these reported data correspond to one of the mouse strains
with higher cloning efficiencies (B6D2F1), and the effects of genotype on cloning rates are
well-described [18]. Indeed, our null full-term developmental rates in the non-treated SCNT
embryos agree with the results of other studies performed on the B6CBAF1 strain [14, 25, 58].
In summary, the present study demonstrates that: (1) VitC improves both in vitro and in
vivo development of mouse SCNT embryos through a yet unknown mechanism, as no effects
on nuclear reprogramming could be detected; (2) the combination of VitC with PsA does not
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show significant additive effects on mouse SCNT efficiency, although full-term development is
slightly increased with regards to treatments with VitC or PsA alone; (3) the use of LatA during
micromanipulation and activation procedures improves blastocyst formation in non-treated
cloned embryos, but its enhancement of mouse cloning efficiencies requires the treatment of
embryos with an epigenetic modifier.
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